Alvox Bio LTD

Alvox Bio is a pioneering CRO specializing in 3D bioprinting. We deliver customized, high-precision models that accelerate drug discovery, enable tissue engineering, and advance personalized medicine while reducing in vivo testing.

The platform is modular and translates complex biology into structured experimental systems in three stages. Tailored design builds each model around the disease context, tissue environment and study objectives. Advanced engineering uses defined workflows and automated processes to produce bioprinted models with precise control, reproducibility and scalable experimentation. Deep characterization applies multiparametric analysis to validate model quality and generate biological insight. The models are designed in line with New Approach Methodologies (NAMs) principles: a defined context of use, demonstrated human biological relevance, deep technical characterization and fit-for-purpose performance. Dynamic, perfusable lung-on-a-chip systems capture lung tissue context under controlled flow. For immune-competent models, the company builds 3D skin models in stages: a stable epidermis–dermis baseline, controlled introduction of immune components, and modeling of immune–tissue interactions while maintaining reproducibility.

Biotech companies; pharmaceutical companies; research organizations.

Ziv Heller - CEO & Co-Founder

Liat Shachnai-Pinkas - CTO